Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
69 hedge funds and large institutions have $93.7M invested in Catalyst Pharmaceutical in 2017 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 7 closing their positions.
894% more call options, than puts
Call options by funds: $1.08M | Put options by funds: $109K
286% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 7
90% more capital invested
Capital invested by funds: $49.3M → $93.7M (+$44.4M)
42% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 12
38% more funds holding
Funds holding: 50 → 69 (+19)
10.01% more ownership
Funds ownership: 30.5% → 40.51% (+10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.33M |
| 2 |
JP Morgan Chase
New York
|
+$3.04M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.86M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.44M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$1.77M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.71M |
| 3 |
CA
Corrado Advisors
Ramsey,
New Jersey
|
-$239K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$140K |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$83.5K |
CPRX Hedge Fund Activity: Q2 2017 in Review
69 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2017, worth a combined $93.7M — up 90% from $49.3M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CPRX positions and 7 closed out — a net gain of 20 holders — while 17 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $6.33M. The largest seller was Broadfin Capital, cutting an estimated $1.77M.
- 69 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2017, up from 50 in Q1 2017.
- Funds reported $93.7M of Catalyst Pharmaceutical stock for Q2 2017, up 90% quarter-over-quarter.
- 27 funds opened new Catalyst Pharmaceutical positions in Q2 2017 and 7 closed out, a net change of +20 holders.
- The largest Catalyst Pharmaceutical buyer in Q2 2017 was BlackRock, an estimated $6.33M added.
- The largest Catalyst Pharmaceutical seller in Q2 2017 was Broadfin Capital, an estimated $1.77M sold.
Based on aggregated 13F filings for Q2 2017.